These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Ursodeoxycholic acid--new drug for liver diseases. Dasarathy S; Acharya SK Trop Gastroenterol; 1993; 14(1):1-2. PubMed ID: 8342242 [No Abstract] [Full Text] [Related]
8. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168 [TBL] [Abstract][Full Text] [Related]
9. Rationale for therapy with ursodeoxycholic acid in patients with cholestatic liver disease. van Erpecum KJ; van de Meeberg PC; van Berge Henegouwen GP Neth J Med; 1993 Dec; 43(5-6):233-8. PubMed ID: 8107930 [TBL] [Abstract][Full Text] [Related]
10. [Non-hepatic manifestations of the overlap syndrome (a case report)]. Mikheeva OM; Il'chenko LIu Eksp Klin Gastroenterol; 2006; (6):116-25. PubMed ID: 17612105 [No Abstract] [Full Text] [Related]
11. [Giant biliary lithiasis and nasobiliary drainage. Is it history?]. Ballesteros Amozurrutia MA; Falcón Martínez MA Rev Gastroenterol Mex; 1996; 61(1):47-8. PubMed ID: 8685592 [No Abstract] [Full Text] [Related]
12. [Treatment of primary biliary cirrhosis. The effect of ursodeoxycholic acid is questioned now]. Broomé U Lakartidningen; 2000 May; 97(21):2585-7. PubMed ID: 10881517 [No Abstract] [Full Text] [Related]
13. [Drug-induced cholelitholysis]. Swobodnik W Dtsch Med Wochenschr; 1992 Oct; 117(44):1694. PubMed ID: 1425277 [No Abstract] [Full Text] [Related]
14. [Bile acids in therapy of liver diseases]. Leuschner U Internist (Berl); 1994 Dec; 35(12):1147-55. PubMed ID: 7883518 [No Abstract] [Full Text] [Related]
15. [Treatment of autoimmune hepatic diseases]. Bueverov AO Klin Med (Mosk); 2004; 82(10):62-6. PubMed ID: 15584604 [TBL] [Abstract][Full Text] [Related]
16. Complementary stimulation of hepatobiliary transport and detoxification by rifampicin and ursodeoxycholic acid in humans. Duttala S; Tobi M; Dingell JD Gastroenterology; 2006 Feb; 130(2):619-20; author reply 620. PubMed ID: 16472623 [No Abstract] [Full Text] [Related]
17. [Ursodeoxycholic acid as the main treatment of hepatobiliary diseases in children and teenagers]. Reĭzis AR; Nikitina TS; Drondina AK; Anan'eva NP; Stulov AP Ross Gastroenterol Zh; 2001; (1):86-91. PubMed ID: 11565130 [No Abstract] [Full Text] [Related]
18. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Günsar C; Melek M; Karaca I; Sencan A; Mir E; Ortaç R; Canan O Hepatogastroenterology; 2002; 49(44):497-500. PubMed ID: 11995481 [TBL] [Abstract][Full Text] [Related]
19. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Willot S; Uhlen S; Michaud L; Briand G; Bonnevalle M; Sfeir R; Gottrand F Pediatrics; 2008 Dec; 122(6):e1236-41. PubMed ID: 19029197 [TBL] [Abstract][Full Text] [Related]
20. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Lindblad A; Glaumann H; Strandvik B Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]